CXCR3

CXCR3

CXCR3 분자 정보

Molecule Name
C-X-C motif chemokine receptor 3
분자 별명
CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R, Mig-R, MigR
Drug Development Progress
임상 약물 수2
시판 약물 수0
최고 연구 개발 단계Phase 1 Clinical
표적 별명
CKR-L2,G protein-coupled receptor 9,IP-10 receptor,CXCR-3,CXC-R3,CXCR3,C-X-C Motif Chemokine Receptor 3,Interferon-Inducible Protein 10 Receptor,GPR9,C-X-C Chemokine Receptor Type 3,Chemokine Receptor 3,CD183 Antigen,CMKAR3,Chemokine (C-X-C Motif) Receptor 3,Mig Receptor,IP10-R,CD182,CD183,Mig-R,MigR,Receptors, CXCR3
분자 배경
Chemokines are proteins which induce chemotaxis, promote differentiation of immune cells, and cause tissue extravasation. Given these properties, their role in anti-tumor immune response in the cancer environment is of great interest. Although immunotherapy has shown clinical benefit for some cancer patients, other patients do not respond. One of the mechanisms of resistance to checkpoint inhibitors may be chemokine signaling. The CXCL9, -10, -11/CXCR3 axis regulates immune cell migration, differentiation, and activation, leading to tumor suppression (paracrine axis). However, there are some reports that show involvements of this axis in tumor growth and metastasis (autocrine axis). Thus, a better understanding of CXCL9, -10, -11/CXCR3 axis is necessary to develop effective cancer control.

CXCR3 제품 목록

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
OCU-110OCU-10-C-110; OGX-110; OCU-110Phase 1 ClinicalOcugenix Corp
Macular Degeneration
상세
ACT-777991ACT-777991Phase 1 ClinicalIdorsia Pharmaceuticals Ltd
Diabetes Mellitus, Type 1; Inflammation
상세